Tags

Type your tag names separated by a space and hit enter

Adjuvant use of melatonin for treatment of fibromyalgia.

Abstract

Fibromyalgia syndrome (FMS) is a chronic musculoskeletal disorder characterized by generalized muscular pain accompanied by fatigue and tenderness at specific anatomic sites called tender points. Although preliminary evidence indicates that melatonin may be effective in treating the pain associated with FMS, no definitive evidence supports this claim. This study was designed to evaluate the significance of using different doses of melatonin, alone or in combination with fluoxetine for the management of FMS. A double-blind, placebo-controlled clinical study was performed on 101 patients (95 women and 6 men) who fulfilled the criteria of the American College of Rheumatology (ACR) of FMS. The patients were randomized into four groups: group A (24 patients) treated with 20 mg/day fluoxetine alone; group B (27 patients) treated with melatonin 5 mg alone; group C (27 patients) treated with 20 mg fluoxetine plus 3 mg melatonin; group D (23 patients) treated with 20 mg fluoxetine plus 5 mg melatonin. Both drugs were given once daily in the morning and night time, respectively, for 8 wk. Each patient was clinically evaluated through direct interview with the patients using the Fibromyalgia Impact Questionnaire (FIQ) at zero time and after 8 wk. Using melatonin (3 mg or 5 mg/day) in combination with 20 mg/day fluoxetine resulted in significant reduction in both total and different components of FIQ score compared to the pretreatment values. In conclusion, administration of melatonin, alone or in a combination with fluoxetine, was effective in the treatment of patients with FMS.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq. saad_alzaidi@yahoo.com

    , ,

    Source

    Journal of pineal research 50:3 2011 Apr pg 267-71

    MeSH

    Adolescent
    Adult
    Aged
    Double-Blind Method
    Drug Therapy, Combination
    Female
    Fibromyalgia
    Fluoxetine
    Humans
    Male
    Melatonin
    Middle Aged
    Treatment Outcome
    Young Adult

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    21158908

    Citation

    Hussain, Saad Abdul-Rehman, et al. "Adjuvant Use of Melatonin for Treatment of Fibromyalgia." Journal of Pineal Research, vol. 50, no. 3, 2011, pp. 267-71.
    Hussain SA, Al-Khalifa II, Jasim NA, et al. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res. 2011;50(3):267-71.
    Hussain, S. A., Al-Khalifa, I. I., Jasim, N. A., & Gorial, F. I. (2011). Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research, 50(3), pp. 267-71. doi:10.1111/j.1600-079X.2010.00836.x.
    Hussain SA, et al. Adjuvant Use of Melatonin for Treatment of Fibromyalgia. J Pineal Res. 2011;50(3):267-71. PubMed PMID: 21158908.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Adjuvant use of melatonin for treatment of fibromyalgia. AU - Hussain,Saad Abdul-Rehman, AU - Al-Khalifa,Ihab Ibrahim, AU - Jasim,Nizar Abdullatif, AU - Gorial,Faiq Isho, Y1 - 2010/12/16/ PY - 2010/12/17/entrez PY - 2010/12/17/pubmed PY - 2011/6/24/medline SP - 267 EP - 71 JF - Journal of pineal research JO - J. Pineal Res. VL - 50 IS - 3 N2 - Fibromyalgia syndrome (FMS) is a chronic musculoskeletal disorder characterized by generalized muscular pain accompanied by fatigue and tenderness at specific anatomic sites called tender points. Although preliminary evidence indicates that melatonin may be effective in treating the pain associated with FMS, no definitive evidence supports this claim. This study was designed to evaluate the significance of using different doses of melatonin, alone or in combination with fluoxetine for the management of FMS. A double-blind, placebo-controlled clinical study was performed on 101 patients (95 women and 6 men) who fulfilled the criteria of the American College of Rheumatology (ACR) of FMS. The patients were randomized into four groups: group A (24 patients) treated with 20 mg/day fluoxetine alone; group B (27 patients) treated with melatonin 5 mg alone; group C (27 patients) treated with 20 mg fluoxetine plus 3 mg melatonin; group D (23 patients) treated with 20 mg fluoxetine plus 5 mg melatonin. Both drugs were given once daily in the morning and night time, respectively, for 8 wk. Each patient was clinically evaluated through direct interview with the patients using the Fibromyalgia Impact Questionnaire (FIQ) at zero time and after 8 wk. Using melatonin (3 mg or 5 mg/day) in combination with 20 mg/day fluoxetine resulted in significant reduction in both total and different components of FIQ score compared to the pretreatment values. In conclusion, administration of melatonin, alone or in a combination with fluoxetine, was effective in the treatment of patients with FMS. SN - 1600-079X UR - https://www.unboundmedicine.com/medline/citation/21158908/full_citation L2 - https://doi.org/10.1111/j.1600-079X.2010.00836.x DB - PRIME DP - Unbound Medicine ER -